Karakaya Caner, Kilic Seyma, Yildirim Isik
Department of Ophthalmology, Istanbul Medipol University, Faculty of Medicine, Istanbul, Turkey.
Department of Neurology, Istanbul Medipol University, Faculty of Medicine, Istanbul, Turkey.
Medicine (Baltimore). 2025 Jul 11;104(28):e43292. doi: 10.1097/MD.0000000000043292.
This study aimed to assess pupillometry changes and alterations in clinical headache severity following brimonidine tartrate 0.15% administration in patients with acute migraine attacks.
A randomized controlled prospective study was conducted involving 42 patients with acute migraine attacks and 48 healthy individuals in the control group. Infrared pupillometry and Visual Analog Scale measurements were assessed before and after ocular instillation of brimonidine tartrate 0.15%.
In patients with acute migraine attacks, the mean latency was 156 ms compared with 173 ms in the control group (P = .042). Pupillary amplitude was 2.45 mm in the acute migraine group and 2.91 mm in the control group (P = .041). Both groups exhibited a statistically significant decrease in pupillary diameter after the administration of brimonidine tartrate 0.15% in dynamic and static pupillometry. However, latency was significantly prolonged in the acute migraine group (P = .009), whereas no significant change was observed in the control group (P > .05). Although there was a statistically significant decrease in the anterior chamber depth in the migraine group after brimonidine tartrate 0.15% (P = .005), the decrease in the control group was not significant (P = .052). Visual Analog Scale scores significantly decreased in patients with acute migraine patients after brimonidine (P < .001).
The study findings suggest that patients experiencing acute migraine attacks demonstrate shorter pupillary constriction latencies, indicating the presence of accompanying sympathetic hypoactivity in migraine patients. Latency prolongation after brimonidine suggests sympathetic hyperfunction secondary to chronic sympathetic hypofunction in migraine patients. Brimonidine, with its ability to cross the blood-brain barrier, may provide pain relief through a mechanism similar to that of latency prolongation. This study sheds light on the potential role of brimonidine tartrate in the management of acute migraine attacks, and highlights its effects on pupillometric parameters, thereby contributing to our understanding of migraine pathophysiology and potential treatment avenues.
本研究旨在评估0.15%酒石酸溴莫尼定给药后,急性偏头痛发作患者的瞳孔测量变化及临床头痛严重程度的改变。
进行了一项随机对照前瞻性研究,纳入42例急性偏头痛发作患者和48例健康个体作为对照组。在滴入0.15%酒石酸溴莫尼定前后,评估红外瞳孔测量和视觉模拟量表测量结果。
急性偏头痛发作患者的平均潜伏期为156毫秒,而对照组为173毫秒(P = 0.042)。急性偏头痛组的瞳孔幅度为2.45毫米,对照组为2.91毫米(P = 0.041)。在动态和静态瞳孔测量中,两组在给予0.15%酒石酸溴莫尼定后瞳孔直径均有统计学意义的减小。然而,急性偏头痛组的潜伏期显著延长(P = 0.009),而对照组未观察到显著变化(P > 0.05)。虽然0.15%酒石酸溴莫尼定给药后偏头痛组前房深度有统计学意义的减小(P = 0.005),但对照组的减小不显著(P = 0.052)。酒石酸溴莫尼定给药后,急性偏头痛患者的视觉模拟量表评分显著降低(P < 0.001)。
研究结果表明,急性偏头痛发作患者的瞳孔收缩潜伏期较短,表明偏头痛患者存在伴随的交感神经功能减退。酒石酸溴莫尼定给药后潜伏期延长表明偏头痛患者慢性交感神经功能减退继发交感神经功能亢进。酒石酸溴莫尼定能够穿过血脑屏障,可能通过类似于潜伏期延长的机制提供疼痛缓解。本研究揭示了酒石酸溴莫尼定在急性偏头痛发作管理中的潜在作用,并突出了其对瞳孔测量参数的影响,从而有助于我们理解偏头痛的病理生理学和潜在治疗途径。